|
Hematologic Malignancy Grand Rounds - FY18 Leveraging MRD in DLBCL After CAR Therapy |
10/20/2017 - 9:00am to 10:15am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Mantle Cell Lymphoma: Prognostic Markers and Approaches to the Elderly |
10/27/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Microparticles and Cancer |
03/23/2018 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 New insights on T and NKT cell lymphoma from the Singapore Lymphoma Study Group |
05/11/2018 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Optimizing the Safety of Chimeric Antigen Receptor Modified T Cells |
09/22/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Peculiarities of Primary Mediastinal B-cell Lymphoma |
08/25/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 PG545, A Novel Anti-Neoplastic Immunomodulator |
09/08/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Relapse following allogeneic HSCT: Should I use a donor lymphocyte infusion (DLI) or a checkpoint inhibitor antibody |
02/09/2018 - 9:00am to 10:00am EST |
|
Hematologic Malignancy Grand Rounds - FY18 Relapsed DLBCL CAR T Cells for the Cure or A Bridge to Allogeneic Transplant |
05/18/2018 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Smoldering Multiple Myeloma Treat or Not to Treat Who Won the Debate |
04/20/2018 - 9:00am to 10:00am EDT |
Facebook
Twitter
LinkedIn
Forward